CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma. A systematic review and meta-analysis

European Journal of Radiology

Volumn 71, Issue 1, 2009, Pages 164-174

  Gu, Ping ^a   Pan, Ling Ling ^a   Wu, Shu Qi ^a   Sun, Li ^a   Huang, Gang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CA 125; CT; Meta analysis; MRI; PET; Recurrent ovarian carcinoma

Indexed keywords

CA 125; CT; META-ANALYSIS; MRI; PET; RECURRENT OVARIAN CARCINOMA;

COMPUTERIZED TOMOGRAPHY;

CHEMOTHERAPY;

CA 125 ANTIGEN; GADOLINIUM;

ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MEDICAL LITERATURE; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

CA-125 ANTIGEN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 67649185136     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.02.019     Document Type: Article

References (70)

1. Einhorn N., Nilsson B., and Sjovall K. Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population. Cancer 55 9 (1985) 2019-2025
2. Boring C.C., Squires T.S., Tong T., and Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 44 1 (1994) 7-26
3. Berek J.S., Trope C., and Vergote I. Surgery during chemotherapy and at relapse of ovarian cancer. Ann Oncol 10 Suppl 1 (1999) 3-7
4. Armstrong D.K. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7 Suppl 5 (2002) 20-28
5. Vaidya A.P., and Curtin J.P. The follow-up of ovarian cancer. Semin Oncol 30 3 (2003) 401-412
6. Chura J.C., Van Iseghem K., Downs Jr. L.S., Carson L.F., and Judson P.L. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 107 2 (2007) 326-330
7. Megibow A.J., Bosniak M.A., Ho A.G., Beller U., Hulnick D.H., and Beckman E.M. Accuracy of CT in detection of persistent or recurrent ovarian carcinoma: correlation with second-look laparotomy. Radiology 166 2 (1988) 341-345
8. Rubin S.C., Randall T.C., Armstrong K.A., Chi D.S., and Hoskins W.J. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 93 1 (1999) 21-24
9. Rubinstein E., and Knudsen J.B. Clinical aspects of second-look laparotomy in ovarian cancer. Ann Chir Gynaecol 75 3 (1986) 177-179
10. Havrilesky L.J., Kulasingam S.L., Matchar D.B., and Myers E.R. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 97 1 (2005) 183-191
11. Deville W.L., Bezemer P.D., and Bouter L.M. Publications on diagnostic test evaluation in family medicine journals: an optimal search strategy. J Clin Epidemiol 53 1 (2000) 65-69
12. Sackett D.L., and Haynes R.B. The architecture of diagnostic research. BMJ 324 7336 (2002) 539-541
13. Berlin J.A. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet 350 9072 (1997) 185-186
14. Whiting P., Rutjes A.W., Reitsma J.B., Bossuyt P.M., and Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3 (2003) 25
15. Fleiss J.L., Levin B., and Paik M.C. The comparison of proportions from several independent samples: estimation of the marginal mean proportion. In: Fleiss J.L., Levin B., and Paik M.C. (Eds). Statistical methods for rates and proportions. 3rd ed. (2003), John Wiley and Sons, New Jersey 212-217
16. Moses L.E., Shapiro D., and Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 12 14 (1993) 1293-1316
17. Deeks J.J. Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ 323 7305 (2001) 157-162
18. Deville W.L., Buntinx F., Bouter L.M., et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2 (2002) 9
19. Huedo-Medina T.B., Sanchez-Meca J., Marin-Martinez F., and Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index?. Psychol Methods 11 2 (2006) 193-206
20. Zamora J., Abraira V., Muriel A., Khan K., and Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6 (2006) 31
21. Forstner R., Hricak H., Powell C.B., Azizi L., Frankel S.B., and Stern J.L. Ovarian cancer recurrence: value of MR imaging. Radiology 196 3 (1995) 715-720
22. Low R.N., Carter W.D., Saleh F., and Sigeti J.S. Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, In-111-CYT-103 immunoscintigraphy, and CT. Radiology 195 2 (1995) 391-400
23. Folk J.J., Botsford M., and Musa A.G. Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure. Gynecol Oncol 57 2 (1995) 178-182
24. Rustin G.J., Nelstrop A.E., Tuxen M.K., and Lambert H.E. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 7 4 (1996) 361-364
25. Sugiyama T., Nishida T., Komai K., Nishimura H., Yakushiji M., and Nishimura H. Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer. Int J Gynaecol Obstet 54 3 (1996) 251-256
26. Ferrozzi F., Bova D., De Chiara F., et al. Thin-section CT follow-up of metastatic ovarian carcinoma correlation with levels of CA-125 marker and clinical history. Clin Imaging 22 5 (1998) 364-370
27. Low R.N., Saleh F., Song S.Y., et al. Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination-a longitudinal study. Radiology 211 2 (1999) 519-528
28. Kubik-Huch R.A., Dorffler W., von Schulthess G.K., et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 10 5 (2000) 761-767
29. Duan P., and Wang H.Y. Monitoring value of CA125 detection for diagnosis and follow-up survey relapse on ovarian epithelium cancer. J Fudan Univ (Med Sci) 27 5 (2000) 415-418 [in Chinese]
30. Nakamoto Y., Saga T., Ishimori T., et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol 176 6 (2001) 1449-1454
31. Zimny M., Siggelkow W., Schroder W., et al. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 83 2 (2001) 310-315
32. Wang Y., Wu B., Wang G., Xiong G.W., and Wang S.L. Spiral CT in the monitoring of treated ovarian. Cancer J Pract Obstetr Gynecol 17 6 (2001) 340-342 [in Chinese]
33. Coakley F.V., Choi P.H., Gougoutas C.A., et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 223 2 (2002) 495-499
34. Torizuka T., Nobezawa S., Kanno T., et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-d-glucose. Eur J Nucl Med Mol Imaging 29 6 (2002) 797-803
35. Cho S.M., Ha H.K., Byun J.Y., et al. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. AJR Am J Roentgenol 179 2 (2002) 391-395
36. Ricke J., Sehouli J., Hach C., Hanninen E.L., Lichtenegger W., and Felix R. Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol 13 5 (2003) 943-949
37. Picchio M., Sironi S., Messa C., et al. Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment. Q J Nucl Med 47 2 (2003) 77-84
38. Ding X.L., Shen K., Lang J.H., et al. Role of positron emission tomography in diagnosis of recurrent ovarian cancer. Zhonghua Fu Chan Ke Za Zhi 38 11 (2003) 667-669
39. Cheng W.Y., Zhou Q., and Zhu Z.H. The role of [18]F-FDG PET imaging in monitoring recurrent and metastatic ovarian cancer. Chin J Nucl Med 23 2 (2003) 77-79 [in Chinese]
40. Kim S., Chung J.K., Kang S.B., et al. [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. Eur J Nucl Med Mol Imaging 31 2 (2004) 196-201
41. Sironi S., Messa C., Mangili G., et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 233 2 (2004) 433-440
42. Low R.N., Duggan B., Barone R.M., Saleh F., and Song S.Y. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year. Radiology 235 3 (2005) 918-926
43. Takekuma M., Maeda M., Ozawa T., Yasumi K., and Torizuka T. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol 10 3 (2005) 177-181
44. Hauth E.A., Antoch G., Stattaus J., et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur J Radiol 56 2 (2005) 263-268
45. Zhang C.Q., Deng K., Chen J., Song J.Q., and Yao S.Z. The role of 18F-fluorodexyglucose PET-CT imaging in monitoring recurrent and metastatic ovarian cancer. J Shandong Univ (Health Sci) 43 8 (2005) 745-747 [in Chinese]
46. Murakami M., Miyamoto T., Iida T., et al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer 16 Suppl 1 (2006) 99-107
47. Simcock B., Neesham D., Quinn M., Drummond E., Milner A., and Hicks R.J. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 103 1 (2006) 271-276
48. Chung H.H., Kang W.J., Kim J.W., et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 34 4 (2007) 480-486
49. Mangili G., Picchio M., Sironi S., et al. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging 34 5 (2007) 658-666
50. Thrall M.M., DeLoia J.A., Gallion H., and Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 105 1 (2007) 17-22
51. Garcia-Velloso M.J., Jurado M., Ceamanos C., et al. Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma. Eur J Nucl Med Mol Imaging 34 9 (2007) 1396-1405
52. Zhao J., Guan Y.H., Zuo C.T., Hua F.C., and Lin X.T. Value of 18F-FDG PET/CT imaging in detection of postoperative recurrent or metastasis of ovarian cancer. Bull Chin Cancer 16 3 (2007) 187-189 [in Chinese]
53. Gu X., Lou G., Zhang J.W., and Huang Z.L. The application of [18]FDG-PET to diagnose the recurrence of ovarian cancer. Chin J Trauma Disability Med 15 3 (2007) 24-26 [in Chinese]
54. Sebastian S., Lee S.I., Horowitz N.S., et al. PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging 33 1 (2008) 112-118
55. Behbakht K., Randall T.C., Benjamin I., Morgan M.A., King S., and Rubin S.C. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 70 2 (1998) 255-258
56. Ak I., Stokkel M.P., and Pauwels E.K. Positron emission tomography with 2-[18F]fluoro-2-deoxy-d-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol 126 10 (2000) 560-574
57. Kluetz P.G., Meltzer C.C., Villemagne V.L., et al. Combined PET/Ct imaging in oncology. Impact on patient management. Clin Positron Imaging 3 6 (2000) 223-230
58. Martinelli M., Townsend D., Meltzer C., and Villemagne V.V. 7 Survey of results of whole body imaging using the PET/CT at the University of Pittsburgh Medical Center PET facility. Clin Positron Imaging 3 4 (2000) 161
59. Makhija S., Howden N., Edwards R., Kelley J., Townsend D.W., and Meltzer C.C. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol 85 1 (2002) 53-58
60. Bristow R.E., Lagasse L.D., and Karlan B.Y. Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature. Cancer 78 10 (1996) 2049-2062
61. Williams L., Brunetto V.L., Yordan E., DiSaia P.J., and Creasman W.T. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 66 2 (1997) 171-178
62. Miller D.S., Spirtos N.M., Ballon S.C., Cox R.S., Soriero O.M., and Teng N.N. Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer. Cancer 69 2 (1992) 502-510
63. Rustin G.J., Marples M., Nelstrop A.E., Mahmoudi M., and Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 19 20 (2001) 4054-4057
64. Vasey P.A. Management of recurrent epithelial ovarian carcinoma. Aust N Z J Obstet Gynaecol 45 4 (2005) 269-277
65. Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem 48 8 (2002) 1151-1159
66. Funt S.A., Hricak H., Abu-Rustum N., Mazumdar M., Felderman H., and Chi D.S. Role of CT in the management of recurrent ovarian cancer. AJR Am J Roentgenol 182 2 (2004) 393-398
67. Balestreri L., Bison L., Sorio R., Morra A., Campagnutta E., and Morassut S. Abdominal recurrence of ovarian cancer: value of abdominal MR in patients with positive CA125 and negative CT. Radiol Med (Torino) 104 5-6 (2002) 426-436
68. Prayer L., Kainz C., Kramer J., et al. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer. J Comput Assist Tomogr 17 4 (1993) 626-632
69. Patsner B., Orr Jr. J.W., Mann Jr. W.J., Taylor P.T., Partridge E., and Allmen T. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?. Gynecol Oncol 37 3 (1990) 319-322
70. Zanetta G., Rota S., Lissoni A., Meni A., Brancatelli G., and Buda A. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynecol Oncol 81 1 (2001) 63-66